Search research articles
Contact Us
Filters
Showing results (61-70 of 76) with videos related to
Page
of 8
Sort By:
Biochimica Et Biophysica Acta. Molecular Cell Research
|
October 16, 2025
Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancer
Hongxiang Zhang, Matthew R Tonini, Lauren Catherine M Martires, et al.
Molecular Cancer Therapeutics
|
December 23, 2011
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor
Sauveur-Michel Maira, Sabina Pecchi, Alan Huang, et al.
Cancer Research
|
June 10, 2026
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy Efficacy
Alvin Ziying Lu, Brian B Haines, Wenhai Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 28, 2015
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2
Gabriel N Hortobagyi, David Chen, Martine Piccart, et al.
Molecular Cancer Therapeutics
|
October 13, 2022
Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
Antoine Simoneau, Justin L Engel, Madhavi Bandi, et al.
Cancer Cell
|
April 16, 2015
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas
Moshe Elkabets, Evangelos Pazarentzos, Dejan Juric, et al.
Molecular Cancer Therapeutics
|
March 11, 2014
Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials
Christine Fritsch, Alan Huang, Christian Chatenay-Rivauday, et al.
Cancer Research
|
September 7, 2022
VRK1 Is a Synthetic-Lethal Target in VRK2-Deficient Glioblastoma
Julie A Shields, Samuel R Meier, Madhavi Bandi, et al.
Nature
|
November 20, 2014
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Dejan Juric, Pau Castel, Malachi Griffith, et al.
Cancer Research
|
August 10, 2013
An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin
Andrew P Garner, Carl U Bialucha, Elizabeth R Sprague, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 76) with videos related to
Sort By:
Page
of 8
Biochimica Et Biophysica Acta. Molecular Cell Research
|
October 16, 2025
Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancer
Hongxiang Zhang, Matthew R Tonini, Lauren Catherine M Martires, et al.
Molecular Cancer Therapeutics
|
December 23, 2011
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor
Sauveur-Michel Maira, Sabina Pecchi, Alan Huang, et al.
Cancer Research
|
June 10, 2026
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy Efficacy
Alvin Ziying Lu, Brian B Haines, Wenhai Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 28, 2015
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2
Gabriel N Hortobagyi, David Chen, Martine Piccart, et al.
Molecular Cancer Therapeutics
|
October 13, 2022
Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
Antoine Simoneau, Justin L Engel, Madhavi Bandi, et al.
Cancer Cell
|
April 16, 2015
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas
Moshe Elkabets, Evangelos Pazarentzos, Dejan Juric, et al.
Molecular Cancer Therapeutics
|
March 11, 2014
Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials
Christine Fritsch, Alan Huang, Christian Chatenay-Rivauday, et al.
Cancer Research
|
September 7, 2022
VRK1 Is a Synthetic-Lethal Target in VRK2-Deficient Glioblastoma
Julie A Shields, Samuel R Meier, Madhavi Bandi, et al.
Nature
|
November 20, 2014
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Dejan Juric, Pau Castel, Malachi Griffith, et al.
Cancer Research
|
August 10, 2013
An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin
Andrew P Garner, Carl U Bialucha, Elizabeth R Sprague, et al.
Page
of 8